FOLFOX / Bevacizumab (Beva) +/- Irinotecan in advanced colorectal cancer (CRC): A randomized phase II trial (AIO KRK 0209, CHARTA)
Hans‐Joachim Schmoll(Martin Luther University Halle-Wittenberg), Alexander Stein(Universität Hamburg), Bert Hildebrandt(Charité - Universitätsmedizin Berlin), Benjamin Garlipp(University Hospital Magdeburg), Jörg Steighardt, Thomas Göhler, Fabian Maximilian Meinert(Charité - Universitätsmedizin Berlin), Heinz‐Gert Hoeffkes(Klinikum Fulda), Malte Leithäuser(University of Rostock), A. Florschütz(Städtisches Klinikum Dessau), Thomas Edelmann(Praxis für Hämatologie und Onkologie), Ulrich Kaiser(University of Applied Sciences Landshut), Arndt Vogel(Princess Margaret Cancer Centre), Helmut Forstbauer, Stephan Kanzler(Leopoldina Krankenhaus Schweinfurt), Carla Hannig(Praxis für Hämatologie und Onkologie), Christian Junghanß(University of Rostock), Joern Ruessel, Michael Schaefers(Praxis für Hämatologie und Onkologie), Franziska Cygon(University Hospital in Halle)
Cited by 1
Related Papers
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making
|Annals of Oncology|2012|1.5k
Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
|Annals of Oncology|2022|1.4k
NASH limits anti-tumour surveillance in immunotherapy-treated HCC
|Nature|2021|1.3k